{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-082723","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.253685+00:00","generated_at":"2026-06-04T04:59:45.773376+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NewAmsterdam Pharma appoints Juliette Audet as CBO, effective April 1, 2024","bullets":["Juliette Audet appointed Chief Business Officer, effective April 1, 2024.","Audet resigns from Board of Directors; no disagreement with company.","Audet was a Partner at Forbion and previously on the Board since 2020.","Company expects two pivotal readouts for obicetrapib in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-082723","json":"https://secwatch.observer/filing/0001193125-24-082723.json","markdown":"https://secwatch.observer/filing/0001193125-24-082723.md","text":"https://secwatch.observer/filing/0001193125-24-082723.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/0001193125-24-082723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/d800417d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:59:45.773376+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e0c8a57a6","claim":"Juliette Audet resigned as Director at NewAmsterdam Pharma Co N.V..","evidence_excerpt":"In connection with Ms. Audet’s appointment as CBO, the Company’s board of directors (the “Board”) and Ms. Audet determined, as of March 28, 2024, that she will resign, effective April 1, 2024, from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/0001193125-24-082723-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d0e70ee56b","claim":"Juliette Audet was appointed as Chief Business Officer at NewAmsterdam Pharma Co N.V..","evidence_excerpt":"On April 1, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) announced the appointment of Juliette Audet as Chief Business Officer (“CBO”) of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524082723/0001193125-24-082723-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}